Dawn M. Zier
Dawn M. Zier's purchase track record
How the stock did after each of Dawn M. Zier's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/9/2025 | HAIN | $320K | +3.2% | -24.1% | +18.9% |
| 11/15/2023 | HAIN | $56K | -16.7% | -35.0% | +17.9% |
| 3/3/2022 | PRPL | $139K | -36.8% | -54.8% | -9.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Hain Celestial Focuses on Leaner Business Structure. Hain Celestial is moving toward a leaner business model as part of its ongoing turnaround efforts. The company is working to simplify its operations, a move that investors are watching to see if it can stabilize the stock. With the share price currently trading near its 52-week low, the market is closely monitoring whether these structural changes will lead to improved performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
No recent PRPL news found; context limited to technicals. The provided news article concerns Kimberly-Clark and does not relate to Purple Innovation. Therefore, no specific recent corporate developments can be summarized for this symbol. Technical indicators show the stock is in an oversold zone with high volatility, but without relevant news, the primary driver of current sentiment remains unclear.
Transaction History
| PBH | ▲ Buy | Grant | 2,981 | $0 | 8/4/2026 | View on chart |
| HAIN | ▲ Buy | Grant | 114,729 | $0 | 10/30/2025 | View on chart |
| PBH | ▲ Buy | Grant | 2,094 | $0 | 8/5/2025 | View on chart |
| HAIN | ▲ Buy | Open Market | 200,000 | $320K | 5/9/2025 | View on chart |
| HAIN | ▲ Buy | Grant | 19,474 | $0 | 10/31/2024 | View on chart |
| PBH | ▲ Buy | Grant | 2,202 | $0 | 8/6/2024 | View on chart |
| HAIN | ▲ Buy | Open Market | 5,000 | $56K | 11/15/2023 | View on chart |
| HAIN | ▲ Buy | Grant | 15,098 | $0 | 10/26/2023 | View on chart |
| PBH | ▲ Buy | Grant | 2,295 | $0 | 8/1/2023 | View on chart |
| PRPL | ▼ Sell | Other | 424 | — | 4/27/2023 | View on chart |
| HAIN | ▲ Buy | Grant | 8,346 | $0 | 11/17/2022 | View on chart |
| PBH | ▲ Buy | Grant | 2,495 | $0 | 8/2/2022 | View on chart |
| PRPL | ▲ Buy | Grant | 17,947 | $0 | 5/17/2022 | View on chart |
| PRPL | ▲ Buy | Open Market | 20,000 | $139K | 3/3/2022 | View on chart |
| HAIN | ▲ Buy | Grant | 5,410 | $0 | 10/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Prestige Consumer Healthcare Reports Q1 2027 Earnings
Prestige Consumer Healthcare released the transcript of its Q1 2027 earnings call. The company discussed its quarterly results and outlook, providing detailed guidance on revenue, earnings, and future plans. The release offers investors a clearer view of the company's performance and strategy.
Prestige Consumer Healthcare Reports Q1 2027 Earnings. Prestige Consumer Healthcare released the transcript of its Q1 2027 earnings call. The company discussed its quarterly results and outlook, providing detailed guidance on revenue, earnings, and future plans. The release offers investors a clearer view of the company's performance and strategy.